Snibe Diagnostic SARS-CoV-2 Antigen Assay Secures CE Mark
By HospiMedica International staff writers Posted on 17 Mar 2021 |
Image: Maglumi SARS-CoV-2 Ag (CLIA) Kit (Photo courtesy of Snibe Diagnostic)
Snibe Diagnostic (Shenzhen, China) has received CE-IVD marking for its Maglumi SARS-CoV-2 Ag antigen test and has launched the test in countries accepting the designation.
The MAGLUMI SARS-CoV-2 Ag with CE mark is a chemiluminescence immunoassay solution for the quantitative detection of nucleocapsid antigens of SARS-CoV-2 in nasopharyngeal and oropharyngeal swab samples taken from suspected COVID-19 patients. The assay has demonstrated 97.7% sensitivity and 99.6% specificity, and could aid in the early detection of SARS-CoV-2 virus from suspected COVID-19 cases.
The MAGLUMI SARS-CoV-2 Ag assay runs on all MAGLUMI fully-auto chemiluminescence immunoassay analyzers which are widely available around the world. The SARS-CoV-2 antigen assay can shorten the TAT and simplify operation procedure to improve the efficiency of clinical diagnosis when compared with RT-PCR molecular testing, making it more applicable for large-scale testing.
Related Links:
The MAGLUMI SARS-CoV-2 Ag with CE mark is a chemiluminescence immunoassay solution for the quantitative detection of nucleocapsid antigens of SARS-CoV-2 in nasopharyngeal and oropharyngeal swab samples taken from suspected COVID-19 patients. The assay has demonstrated 97.7% sensitivity and 99.6% specificity, and could aid in the early detection of SARS-CoV-2 virus from suspected COVID-19 cases.
The MAGLUMI SARS-CoV-2 Ag assay runs on all MAGLUMI fully-auto chemiluminescence immunoassay analyzers which are widely available around the world. The SARS-CoV-2 antigen assay can shorten the TAT and simplify operation procedure to improve the efficiency of clinical diagnosis when compared with RT-PCR molecular testing, making it more applicable for large-scale testing.
Related Links:
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans